Cargando…
A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Higher Education Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777975/ https://www.ncbi.nlm.nih.gov/pubmed/28677103 http://dx.doi.org/10.1007/s13238-017-0438-y |
| _version_ | 1783294264234475520 |
|---|---|
| author | Kang, Ciming Xia, Lin Chen, Yuanzhi Zhang, Tianying Wang, Yiwen Zhou, Bing You, Min Yuan, Quan Tzeng, Chi-Meng An, Zhiqiang Luo, Wenxin Xia, Ningshao |
| author_facet | Kang, Ciming Xia, Lin Chen, Yuanzhi Zhang, Tianying Wang, Yiwen Zhou, Bing You, Min Yuan, Quan Tzeng, Chi-Meng An, Zhiqiang Luo, Wenxin Xia, Ningshao |
| author_sort | Kang, Ciming |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5777975 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Higher Education Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-57779752018-02-01 A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys Kang, Ciming Xia, Lin Chen, Yuanzhi Zhang, Tianying Wang, Yiwen Zhou, Bing You, Min Yuan, Quan Tzeng, Chi-Meng An, Zhiqiang Luo, Wenxin Xia, Ningshao Protein Cell Letter Higher Education Press 2017-07-04 2018-01 /pmc/articles/PMC5777975/ /pubmed/28677103 http://dx.doi.org/10.1007/s13238-017-0438-y Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| spellingShingle | Letter Kang, Ciming Xia, Lin Chen, Yuanzhi Zhang, Tianying Wang, Yiwen Zhou, Bing You, Min Yuan, Quan Tzeng, Chi-Meng An, Zhiqiang Luo, Wenxin Xia, Ningshao A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys |
| title | A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys |
| title_full | A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys |
| title_fullStr | A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys |
| title_full_unstemmed | A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys |
| title_short | A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys |
| title_sort | novel therapeutic anti-hbv antibody with increased binding to human fcrn improves in vivo pk in mice and monkeys |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777975/ https://www.ncbi.nlm.nih.gov/pubmed/28677103 http://dx.doi.org/10.1007/s13238-017-0438-y |
| work_keys_str_mv | AT kangciming anoveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT xialin anoveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT chenyuanzhi anoveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT zhangtianying anoveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT wangyiwen anoveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT zhoubing anoveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT youmin anoveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT yuanquan anoveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT tzengchimeng anoveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT anzhiqiang anoveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT luowenxin anoveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT xianingshao anoveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT kangciming noveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT xialin noveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT chenyuanzhi noveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT zhangtianying noveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT wangyiwen noveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT zhoubing noveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT youmin noveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT yuanquan noveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT tzengchimeng noveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT anzhiqiang noveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT luowenxin noveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys AT xianingshao noveltherapeuticantihbvantibodywithincreasedbindingtohumanfcrnimprovesinvivopkinmiceandmonkeys |